Chemokine RANTES in severe pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 165, Issue 4, 2002, Pages 534-539

  Dorfmüller, Peter ^a   Zarka, Véronique ^b   Durand Gasselin, Ingrid ^c   Monti, Gianpaola ^a   Balabanian, Karl ^b   Garcia, Gilles ^c   Capron, Frédérique ^c   Coulomb Lherminé, Aurore ^c   Marfaing Koka, Anne ^a   Simonneau, Gérald ^b   Emilie, Dominique ^a   Humbert, Marc ^a,c  

^a UPRES EA 2705   (France)

^b INSERM   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Chemokines; Endothelial cells; Primary pulmonary hypertension; Pulmonary hypertension; RANTES

Indexed keywords

CD45 ANTIGEN; RANTES; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; T LYMPHOCYTE;

EID: 0037084245     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.165.4.2012112     Document Type: Article

References (52)

1. Primary pulmonary hypertension
2. Risk factors for pulmonary arterial hypertension
3. Heterozygous germline mutations in a TGF-β receptor, BMPR2, are the cause of familial primary pulmonary hypertension
4. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
5. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family
6. BMPR2 haploinsufficiency as the inherited mechanism for primary pulmonary hypertension
7. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia
8. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension
9. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension
10. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients
11. Exuberant endothelial cell growth and element of inflammation are present in plexiform lesions of pulmonary hypertension
12. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
13. Chemokines - Chemotactic cytokines that mediate inflammation
14. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES
15. Quantification of cytokine gene expression by competitive PCR using a colorimetric assay
16. Production of interleukins in human immunodeficiency virus-1 replicating lymph nodes
17. Histopathology of primary pulmonary hypertension: A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung and Blood Institute, primary pulmonary hypertension registry
18. Increased plasma serotonin in primary pulmonary hypertension
19. High plasma serotonin levels in primary pulmonary hypertension: Effect of long-term epoprostenol (prostacyclin) therapy
20. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension
21. Endothelial dysfunction in pulmonary hypertension
22. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
23. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
24. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
25. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
26. Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension
27. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension
28. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension
29. Primary pulmonary hypertension: Natural history and the importance of thrombosis
30. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
31. Endothelium dysfunction in severe pulmonary arterial hypertension: Elevated plasma and pulmonary vascular adhesion molecules
32. Chemokine MIP-1α expression in lung biopsies of primary pulmonary hypertension
33. In situ analysis of C-C chemokine mRNA in human glomerulonephritis
34. Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease
35. Interleukin-6 and RANTES in Takayasu arteritis: A guide for therapeutic decisions?
36. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II
37. Identification and characterization of a potent, selective and orally active antagonist of the CC chemokine receptor-1
38. 1Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: Blocking monocyte arrest and recruitment
39. Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells
40. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with primary pulmonary hypertension
41. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
42. TGF-β 1 reciprocally controls chemotaxis of human peripheral blood monocyte derived dendritic cells via chemokine receptors
43. Regulation of the production of the RANTES chemokine by endothelial cells: Synergistic induction by interferon-γ plus TNFα and inhibition by IL-4 and IL-13
44. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
45. Contrasting effects of interleukin-4, interleukin-10 and corticosteroids on RANTES production by human monocytes
46. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: A gene microarray analysis
47. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline
48. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1
49. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension
50. Improvement of severe pulmonary hypertension in a patient with SLE
51. Treatment of pulmonary hypertension secondary to connective tissue diseases
52. Effective immunosuppressive therapy in a patient with primary pulmonary hypertension